首页 > 最新文献

International Journal of Pharmacy Practice最新文献

英文 中文
Screening for chronic kidney disease in community pharmacy: Crierfac project. 社区药房慢性肾脏病筛查:crierface项目。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-11 DOI: 10.1093/ijpp/riaf088
José Espejo-Guerrero, Luis Salar-Ibáñez, Eduardo Satué-de-Velasco, Lourdes Martínez-Berganza-Asensio, Noemí Pérez-León

Objectives: To evaluate the outcomes of chronic kidney disease (CKD) screening in community pharmacies through creatinine measurement and glomerular filtration rate (GFR) estimation in patients meeting specific risk criteria.

Methods: This was a multicenter observational study. People who entered participating pharmacies for any reason and met the inclusion criterion of not having a CKD diagnosis were invited to participate in the study. If they agreed, the pharmacist conducted a point-of-care blood creatinine test, and the GFR was calculated using the CKD-EPI formula. Those with a positive CKD indicator (<45 ml/min/1.73 m2) were referred to their general practitioner (GP) for evaluation. People with a GFR > 60 ml/min/1.73 m2 were not considered to have CKD. Those with a GFR between 45 and 60 ml/min/1.73 m2 were asked to return for reassessment 1 month later. Those with a GFR 45 < ml/min/1.73 m2 were then considered CKD-positive and referred to the GP. All the data were recorded by the pharmacist.

Key findings: One hundred and forty-one community pharmacies from 40 provinces of Spain enrolled 2116 patients. In the first analysis, 1428 (67.5%) were negative, 165 (7.8%) were positive, and 523 (24.7%) needed a second analysis. In the second analysis, 164 (7.8%) were negative, 243 (11.5%) were positive, and 116 (5.5%) did not reattend. In summary, by intention to treat, 1592 (75.2%) were negative and 408 (19.3%) tested positive and were referred to their GP.

Conclusions: The results of CKD detection in community pharmacies are in line with screening in other healthcare settings, confirming they could be a reliable resource in future population-screening strategies.

目的:通过肌酐测定和肾小球滤过率(GFR)评估社区药房慢性肾病(CKD)筛查符合特定风险标准的患者的结果。方法:本研究为多中心观察性研究。任何出于任何原因进入参与药店并符合无CKD诊断纳入标准的人都被邀请参加研究。如果他们同意,药剂师进行了即时血肌酐测试,并使用CKD-EPI公式计算GFR。CKD指标呈阳性(60 ml/min/1.73 m2)的患者不认为患有CKD。GFR在45 - 60ml /min/1.73 m2之间的患者在1个月后再次接受评估。主要发现:来自西班牙40个省的141家社区药房招募了2116名患者。在第一次分析中,1428例(67.5%)为阴性,165例(7.8%)为阳性,523例(24.7%)需要第二次分析。在第二次分析中,164例(7.8%)为阴性,243例(11.5%)为阳性,116例(5.5%)未复发。总之,意向治疗中,1592例(75.2%)呈阴性,408例(19.3%)呈阳性并转介给全科医生。结论:社区药房的CKD检测结果与其他医疗机构的筛查结果一致,证实它们可以作为未来人群筛查策略的可靠资源。
{"title":"Screening for chronic kidney disease in community pharmacy: Crierfac project.","authors":"José Espejo-Guerrero, Luis Salar-Ibáñez, Eduardo Satué-de-Velasco, Lourdes Martínez-Berganza-Asensio, Noemí Pérez-León","doi":"10.1093/ijpp/riaf088","DOIUrl":"https://doi.org/10.1093/ijpp/riaf088","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the outcomes of chronic kidney disease (CKD) screening in community pharmacies through creatinine measurement and glomerular filtration rate (GFR) estimation in patients meeting specific risk criteria.</p><p><strong>Methods: </strong>This was a multicenter observational study. People who entered participating pharmacies for any reason and met the inclusion criterion of not having a CKD diagnosis were invited to participate in the study. If they agreed, the pharmacist conducted a point-of-care blood creatinine test, and the GFR was calculated using the CKD-EPI formula. Those with a positive CKD indicator (<45 ml/min/1.73 m2) were referred to their general practitioner (GP) for evaluation. People with a GFR > 60 ml/min/1.73 m2 were not considered to have CKD. Those with a GFR between 45 and 60 ml/min/1.73 m2 were asked to return for reassessment 1 month later. Those with a GFR 45 < ml/min/1.73 m2 were then considered CKD-positive and referred to the GP. All the data were recorded by the pharmacist.</p><p><strong>Key findings: </strong>One hundred and forty-one community pharmacies from 40 provinces of Spain enrolled 2116 patients. In the first analysis, 1428 (67.5%) were negative, 165 (7.8%) were positive, and 523 (24.7%) needed a second analysis. In the second analysis, 164 (7.8%) were negative, 243 (11.5%) were positive, and 116 (5.5%) did not reattend. In summary, by intention to treat, 1592 (75.2%) were negative and 408 (19.3%) tested positive and were referred to their GP.</p><p><strong>Conclusions: </strong>The results of CKD detection in community pharmacies are in line with screening in other healthcare settings, confirming they could be a reliable resource in future population-screening strategies.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":""},"PeriodicalIF":1.8,"publicationDate":"2025-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145274532","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The evolving role of pharmacists in addressing substance-related harm. 药剂师在解决与物质有关的危害方面不断发展的作用。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-07 DOI: 10.1093/ijpp/riaf080
Jane L Sheridan, Mayyada Wazaify, Suzanne Nielsen
{"title":"The evolving role of pharmacists in addressing substance-related harm.","authors":"Jane L Sheridan, Mayyada Wazaify, Suzanne Nielsen","doi":"10.1093/ijpp/riaf080","DOIUrl":"https://doi.org/10.1093/ijpp/riaf080","url":null,"abstract":"","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":"33 5","pages":"455-457"},"PeriodicalIF":1.8,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145238646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in publicly and privately prescribed anxiolytics in Croatia: do we need a new regulatory framework. 克罗地亚公共和私人处方抗焦虑药的趋势:我们是否需要一个新的监管框架?
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf051
Marta Kučan Štiglić, Tea Strbad, Andrej Belančić, Jasenka Mršić Pelčić, Dinko Vitezić

Objectives: The study aimed to analyse changes in the prescribing trends of anxiolytics in Croatia over the past 15 years, focusing on changes in prescribing patterns and the average cost per defined daily dose (DDD) and to evaluate how frequently patients covered by the Croatian Health Insurance Fund (CHIF) received private prescriptions for anxiolytics.

Methods: Data on total consumption of anxiolytics in Croatia were obtained from two sources: the IMS database and the CHIF database for the period from 2006 to 2022.

Key findings: The total usage of anxiolytic drugs increased from 61.13 DDD/1000 in 2006 to 82.78 DDD/1000 in 2022, an increase of 35.42%, while the financial expenditure in the same period decreased by 15.57%. Diazepam is the anxiolytic drug with the highest prescription rate, with an increase of 67.42%. The highest increase overall was in the total consumption of alprazolam, despite a decrease from 21.22% in 2011 to 16.53% in 2022 in private prescriptions, indicating a substantial increase in prescriptions covered by insurers.

Conclusions: Despite being either not recommended by clinical guidelines or of doubtful efficacy in many cases, prescribing of anxiolytics is common. There is a noticeable increase in anxiolytic drug use in Croatia during the investigated period, while the total financial expenditure has decreased due to price pressure on medications imposed by the national insurer. The high rate of private prescription of anxiolytics is observed. An enhanced national regulatory framework for prescribing anxiolytics in Croatia is needed.

目的:本研究旨在分析克罗地亚过去15年来抗焦虑药处方趋势的变化,重点关注处方模式的变化和每限定日剂量的平均费用,并评估克罗地亚健康保险基金(CHIF)承保的患者接受抗焦虑药私人处方的频率。方法:2006年至2022年期间克罗地亚抗焦虑药物总消费量数据来自两个来源:IMS数据库和CHIF数据库。重点发现:抗焦虑药物总使用量从2006年的61.13 DDD/1000增加到2022年的82.78 DDD/1000,增长35.42%,同期财政支出下降15.57%。安定是处方率最高的抗焦虑药物,增加了67.42%。整体增幅最高的是阿普唑仑的总消费量,尽管私人处方从2011年的21.22%下降到2022年的16.53%,表明保险公司承保的处方大幅增加。结论:尽管临床指南不推荐或在许多情况下疗效可疑,抗焦虑药的处方是常见的。在调查期间,克罗地亚抗焦虑药物的使用明显增加,而由于国家保险公司对药品施加价格压力,财政支出总额减少。私人处方抗焦虑药的比例较高。克罗地亚需要加强抗焦虑药处方的国家监管框架。
{"title":"Trends in publicly and privately prescribed anxiolytics in Croatia: do we need a new regulatory framework.","authors":"Marta Kučan Štiglić, Tea Strbad, Andrej Belančić, Jasenka Mršić Pelčić, Dinko Vitezić","doi":"10.1093/ijpp/riaf051","DOIUrl":"10.1093/ijpp/riaf051","url":null,"abstract":"<p><strong>Objectives: </strong>The study aimed to analyse changes in the prescribing trends of anxiolytics in Croatia over the past 15 years, focusing on changes in prescribing patterns and the average cost per defined daily dose (DDD) and to evaluate how frequently patients covered by the Croatian Health Insurance Fund (CHIF) received private prescriptions for anxiolytics.</p><p><strong>Methods: </strong>Data on total consumption of anxiolytics in Croatia were obtained from two sources: the IMS database and the CHIF database for the period from 2006 to 2022.</p><p><strong>Key findings: </strong>The total usage of anxiolytic drugs increased from 61.13 DDD/1000 in 2006 to 82.78 DDD/1000 in 2022, an increase of 35.42%, while the financial expenditure in the same period decreased by 15.57%. Diazepam is the anxiolytic drug with the highest prescription rate, with an increase of 67.42%. The highest increase overall was in the total consumption of alprazolam, despite a decrease from 21.22% in 2011 to 16.53% in 2022 in private prescriptions, indicating a substantial increase in prescriptions covered by insurers.</p><p><strong>Conclusions: </strong>Despite being either not recommended by clinical guidelines or of doubtful efficacy in many cases, prescribing of anxiolytics is common. There is a noticeable increase in anxiolytic drug use in Croatia during the investigated period, while the total financial expenditure has decreased due to price pressure on medications imposed by the national insurer. The high rate of private prescription of anxiolytics is observed. An enhanced national regulatory framework for prescribing anxiolytics in Croatia is needed.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"515-520"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144560086","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Community pharmacists' counselling practices for topical corticosteroid therapy in the management of atopic dermatitis-a cross-sectional survey. 社区药师对局部皮质类固醇治疗特应性皮炎管理的咨询实践-横断面调查。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf053
Ella Cocoman, Juliette O'Connell, Ana Šešelja Perišin, Josipa Bukić, Doris Rušić, Mihaela Grgić, Dario Leskur

Objectives: Safe and effective use of topical corticosteroids (TCS) relies heavily on appropriate pharmacist counselling in community pharmacies, to optimize treatment and improve outcomes for patients suffering from atopic dermatitis. This study aimed to investigate community pharmacists (CPs)' counselling practices on TCS and their attitudes towards the fingertip unit (FTU) method, patients' knowledge, and adverse drug reactions (ADRs).

Methods: A cross-sectional survey was conducted among CPs in Croatia. A questionnaire was developed, which explored CPs' counselling practices on TCS, their awareness and implementation of the FTU method, and their experience with ADRs. Data was analysed using descriptive statistics.

Key findings: A total of 351 participants engaged with the survey. Over half (57.5%, CI: 52.2%-62.8%) of CPs use a combination of verbal and written counselling, and the majority (>96.6%) explain the dose, method of administration, frequency, and duration of topical corticosteroid therapy to most of their patients. Most (75.2%) are familiar with the FTU method; however, less than half (43.9%) routinely explain it in their counselling. Approximately half of CPs (49%) believe that patients have insufficient information knowledge on the correct TCS application (dose, frequency, and duration of treatment).

Conclusions: CPs' counselling practices focus primarily on the method of administration, frequency, and duration of treatment. CPs have a good awareness of the FTU method, however, are less likely to explain it routinely in practice. Additional education around TCS and ADR training may be beneficial for CPs to enhance their counselling practices.

目的:安全有效地使用局部皮质类固醇(TCS)在很大程度上依赖于社区药房适当的药剂师咨询,以优化治疗并改善特应性皮炎患者的预后。本研究旨在了解社区药师(CPs)对TCS的咨询实践,以及他们对指尖单位(FTU)方法、患者知识和药物不良反应(adr)的态度。方法:对克罗地亚的CPs进行横断面调查。制定了一份调查问卷,探讨了CPs对TCS的咨询实践,他们对FTU方法的认识和实施,以及他们对adr的经验。数据分析采用描述性统计。主要发现:共有351名参与者参与了调查。超过一半(57.5%,CI: 52.2%-62.8%)的CPs使用口头和书面咨询相结合的方法,大多数(bb0 96.6%)向大多数患者解释局部皮质类固醇治疗的剂量、给药方法、频率和持续时间。大多数(75.2%)熟悉FTU方法;然而,不到一半(43.9%)的人在咨询中经常解释这一点。大约一半的CPs(49%)认为患者对正确的TCS应用(剂量、频率和治疗持续时间)缺乏足够的信息知识。结论:CPs的咨询实践主要集中在给药方法、频率和治疗时间上。CPs对FTU方法有很好的认识,然而,在实践中不太可能常规地解释它。关于TCS和ADR培训的额外教育可能有利于CPs加强他们的咨询实践。
{"title":"Community pharmacists' counselling practices for topical corticosteroid therapy in the management of atopic dermatitis-a cross-sectional survey.","authors":"Ella Cocoman, Juliette O'Connell, Ana Šešelja Perišin, Josipa Bukić, Doris Rušić, Mihaela Grgić, Dario Leskur","doi":"10.1093/ijpp/riaf053","DOIUrl":"10.1093/ijpp/riaf053","url":null,"abstract":"<p><strong>Objectives: </strong>Safe and effective use of topical corticosteroids (TCS) relies heavily on appropriate pharmacist counselling in community pharmacies, to optimize treatment and improve outcomes for patients suffering from atopic dermatitis. This study aimed to investigate community pharmacists (CPs)' counselling practices on TCS and their attitudes towards the fingertip unit (FTU) method, patients' knowledge, and adverse drug reactions (ADRs).</p><p><strong>Methods: </strong>A cross-sectional survey was conducted among CPs in Croatia. A questionnaire was developed, which explored CPs' counselling practices on TCS, their awareness and implementation of the FTU method, and their experience with ADRs. Data was analysed using descriptive statistics.</p><p><strong>Key findings: </strong>A total of 351 participants engaged with the survey. Over half (57.5%, CI: 52.2%-62.8%) of CPs use a combination of verbal and written counselling, and the majority (>96.6%) explain the dose, method of administration, frequency, and duration of topical corticosteroid therapy to most of their patients. Most (75.2%) are familiar with the FTU method; however, less than half (43.9%) routinely explain it in their counselling. Approximately half of CPs (49%) believe that patients have insufficient information knowledge on the correct TCS application (dose, frequency, and duration of treatment).</p><p><strong>Conclusions: </strong>CPs' counselling practices focus primarily on the method of administration, frequency, and duration of treatment. CPs have a good awareness of the FTU method, however, are less likely to explain it routinely in practice. Additional education around TCS and ADR training may be beneficial for CPs to enhance their counselling practices.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"501-507"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A cross-sectional study of pharmacy academics' perspectives on the scope of minor ailments in Indonesia and implications for pharmacy education. 横断面研究的药学学者的观点在印尼的小病范围和影响的药学教育。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf052
Vinci Mizranita, Bruce Sunderland, Jeffery David Hughes, Tin Fei Sim

Objectives: To describe pharmacy academics' perceptions of scopes of practice, knowledge, and skills required for the education of pharmacists and pharmacy technicians in the management of minor ailments (MMAs) in Indonesia.

Methods: Online surveys were designed for academic staff teaching pharmacy and pharmacy technician students from all 30 institutions in Central Java, Indonesia. Those teaching both courses received both questionnaires. Percentage of common responses (PCR) described the level of similarity of perceived scopes of practice. Descriptive analyses described respondents' demographics and characteristics.

Key findings: No clear consensus was evident regarding the scopes of MA practice from academics teaching each group of students. The majority of academics teaching pharmacy students perceived that MAs such as migraine and indigestion (with the PCR >80%) should be exclusively managed by pharmacists, showing a strong consensus on the role of pharmacists in managing these ailments. Only a 50%-60% consensus was achieved on the scopes of MAs managed by pharmacy technicians. Some academics perceived pharmacy technicians were not competent to manage any MA. Notably, 52.9% of academics teaching pharmacy students taught management of MAs as a separate course, compared to 26.7% who taught pharmacy technician students.

Conclusions: Discord in the scope of practice perceptions between academics teaching pharmacy and pharmacy technician students requires resolution, including the diverse nature of training involving MMAs. Clearly defined scopes of practice are required to achieve consistent education of MAs for pharmacy and pharmacy technician students.

目的:描述药剂学学者对印度尼西亚管理小病(MMAs)的药剂师和药学技术人员教育所需的实践范围、知识和技能的看法。方法:对印度尼西亚中爪哇所有30所院校的药学和药学技术专业学生的教学人员进行在线调查。两门课的教师都收到了两份问卷。共同反应的百分比(PCR)描述了感知到的实践范围的相似程度。描述性分析描述了受访者的人口统计和特征。主要发现:对于教授每组学生的学者的硕士实践范围,没有明显的明确共识。大多数教授药学专业学生的学者认为,偏头痛和消化不良(PCR率为80%)等MAs应由药剂师专门管理,这表明了对药剂师在管理这些疾病中的作用的强烈共识。在药学技术人员管理的MAs范围上,只有50%-60%的人达成共识。一些学者认为药学技术人员没有能力管理任何文学硕士。值得注意的是,52.9%的教授药剂学学生的学者将硕士管理学作为一门单独的课程来教授,相比之下,26.7%的教授药学技术学生。结论:教授药学和药学技术学生的学者在实践范围认知上的不一致需要解决,包括涉及mma的培训的多样性。明确界定的实践范围需要实现一致的教育硕士药学和药学技术学生。
{"title":"A cross-sectional study of pharmacy academics' perspectives on the scope of minor ailments in Indonesia and implications for pharmacy education.","authors":"Vinci Mizranita, Bruce Sunderland, Jeffery David Hughes, Tin Fei Sim","doi":"10.1093/ijpp/riaf052","DOIUrl":"10.1093/ijpp/riaf052","url":null,"abstract":"<p><strong>Objectives: </strong>To describe pharmacy academics' perceptions of scopes of practice, knowledge, and skills required for the education of pharmacists and pharmacy technicians in the management of minor ailments (MMAs) in Indonesia.</p><p><strong>Methods: </strong>Online surveys were designed for academic staff teaching pharmacy and pharmacy technician students from all 30 institutions in Central Java, Indonesia. Those teaching both courses received both questionnaires. Percentage of common responses (PCR) described the level of similarity of perceived scopes of practice. Descriptive analyses described respondents' demographics and characteristics.</p><p><strong>Key findings: </strong>No clear consensus was evident regarding the scopes of MA practice from academics teaching each group of students. The majority of academics teaching pharmacy students perceived that MAs such as migraine and indigestion (with the PCR >80%) should be exclusively managed by pharmacists, showing a strong consensus on the role of pharmacists in managing these ailments. Only a 50%-60% consensus was achieved on the scopes of MAs managed by pharmacy technicians. Some academics perceived pharmacy technicians were not competent to manage any MA. Notably, 52.9% of academics teaching pharmacy students taught management of MAs as a separate course, compared to 26.7% who taught pharmacy technician students.</p><p><strong>Conclusions: </strong>Discord in the scope of practice perceptions between academics teaching pharmacy and pharmacy technician students requires resolution, including the diverse nature of training involving MMAs. Clearly defined scopes of practice are required to achieve consistent education of MAs for pharmacy and pharmacy technician students.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"526-533"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144553476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Quality prescribing strategy for respiratory conditions in Scotland: improving patient care and promoting environmental sustainability. 苏格兰呼吸系统疾病的质量处方策略:改善患者护理和促进环境可持续性。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf054
Emily Kennedy, Karen Vint, Alpana Mair, Iain Wilson, Lesley Rose, Fiona Eastop, Stuart Law

Objectives: The respiratory prescribing strategy previously published by the Scottish Government did not include any environmental sustainability information and required updating to incorporate this. It was recognized that ~3% of the carbon footprint of NHS Scotland results from the use of pressurized metered dose inhalers due to the high global warming potential of inhaler propellants. The aims of the guide were to support clinicians and people with respiratory illness in the appropriate use of medicines, while applying the principles of value-based health care and realistic medicine, including environmental sustainability. Person-centred medication review, including optimising appropriate inhaler use, is promoted using the 7-step methodology described in the Scottish polypharmacy guidance.

Methods: Stakeholders, including people with lived experience, third sector patient organizations and multidisciplinary team representatives from across primary and secondary care were invited to update the respiratory guide. Open consultation was undertaken before publication. Tools and resources to assist in implementation of the recommendations were developed, including data and patient facing resources.

Key findings: The 'Quality Prescribing Strategy for Respiratory Conditions: a guide for improvement (2024-2027)' was published by the Scottish Government in April 2024. It highlights key recommendations for respiratory prescribing, to improve care of people living with respiratory conditions and to reduce environmental impact of respiratory care.

Conclusions: The guide supports the implementation of national UK-based guidance, including the Scottish Intercollegiate Guidelines Network and National Institute for Health and Care Excellence guidance, together with the indicators and tools to drive improvement in prescribing and patient care by assisting clinicians with practical guidance and prescribing resources. It also supports healthcare organizations and sustainability committees to prioritize actions.

目的:苏格兰政府先前发布的呼吸处方策略没有包括任何环境可持续性信息,需要更新以纳入这一点。人们认识到,由于吸入器推进剂具有较高的全球变暖潜势,苏格兰国民健康服务体系约3%的碳足迹来自使用加压计量吸入器。该指南的目的是支持临床医生和呼吸系统疾病患者适当使用药物,同时适用基于价值的保健和现实医学的原则,包括环境可持续性。以人为中心的药物审查,包括优化适当的吸入器使用,使用苏格兰综合药房指南中描述的7步方法进行推广。方法:邀请利益相关者,包括有生活经验的人、第三部门患者组织和来自初级和二级保健的多学科团队代表更新呼吸指南。出版前已进行公开谘询。开发了协助执行建议的工具和资源,包括数据和面向患者的资源。主要发现:苏格兰政府于2024年4月发布了“呼吸条件的质量处方策略:改进指南(2024-2027)”。它强调了呼吸道处方的主要建议,以改善对呼吸系统疾病患者的护理,并减少呼吸系统护理对环境的影响。结论:该指南支持实施基于英国的国家指南,包括苏格兰校际指南网络和国家健康和护理卓越研究所指南,以及通过协助临床医生提供实用指导和处方资源来推动处方和患者护理改进的指标和工具。它还支持医疗保健组织和可持续发展委员会确定行动的优先次序。
{"title":"Quality prescribing strategy for respiratory conditions in Scotland: improving patient care and promoting environmental sustainability.","authors":"Emily Kennedy, Karen Vint, Alpana Mair, Iain Wilson, Lesley Rose, Fiona Eastop, Stuart Law","doi":"10.1093/ijpp/riaf054","DOIUrl":"10.1093/ijpp/riaf054","url":null,"abstract":"<p><strong>Objectives: </strong>The respiratory prescribing strategy previously published by the Scottish Government did not include any environmental sustainability information and required updating to incorporate this. It was recognized that ~3% of the carbon footprint of NHS Scotland results from the use of pressurized metered dose inhalers due to the high global warming potential of inhaler propellants. The aims of the guide were to support clinicians and people with respiratory illness in the appropriate use of medicines, while applying the principles of value-based health care and realistic medicine, including environmental sustainability. Person-centred medication review, including optimising appropriate inhaler use, is promoted using the 7-step methodology described in the Scottish polypharmacy guidance.</p><p><strong>Methods: </strong>Stakeholders, including people with lived experience, third sector patient organizations and multidisciplinary team representatives from across primary and secondary care were invited to update the respiratory guide. Open consultation was undertaken before publication. Tools and resources to assist in implementation of the recommendations were developed, including data and patient facing resources.</p><p><strong>Key findings: </strong>The 'Quality Prescribing Strategy for Respiratory Conditions: a guide for improvement (2024-2027)' was published by the Scottish Government in April 2024. It highlights key recommendations for respiratory prescribing, to improve care of people living with respiratory conditions and to reduce environmental impact of respiratory care.</p><p><strong>Conclusions: </strong>The guide supports the implementation of national UK-based guidance, including the Scottish Intercollegiate Guidelines Network and National Institute for Health and Care Excellence guidance, together with the indicators and tools to drive improvement in prescribing and patient care by assisting clinicians with practical guidance and prescribing resources. It also supports healthcare organizations and sustainability committees to prioritize actions.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"534-540"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Breathing easier: removing maintenance inhalers from hospital wardstock for cost savings and waste reduction. 呼吸更轻松:从医院病房移除维护吸入器,以节省成本和减少浪费。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf047
Elissa S Y Aeng, Peggy Hung, Alfie Chung, Deborah Heidary, Aaron M Tejani

Background: Maintenance inhalers are commonly used for long-term management of respiratory conditions. These multidose devices contain several weeks of medication, are expensive, and have significant global emissions impact. As these medications are not useful for managing acute symptoms, it was questioned whether keeping these inhalers in hospital wardstock locations may contribute to inhaler wastage.

Objective: To determine if removal of maintenance inhalers from wardstock would reduce the number of inhalers dispensed.

Methods: This was a prospective quality improvement study examining medication utilization data within the Fraser Health Authority. An inventory report was run to determine where maintenance inhalers were located to select hospital sites to target. Maintenance inhalers were removed from wardstock at chosen sites and utilization data from 6 months prior to removal were compared to 6 months post-removal. Outcomes reported were change in number of inhalers dispensed, change in number of inhalers dispensed per active-order-day, change in expenditure, and change in carbon emissions. Informal assessments on workload and access were made during the 6-month follow-up period.

Key findings: Within 6 months after maintenance inhalers were removed from wardstock at two hospitals, 119 fewer inhalers and 43 fewer dry powder inhaler capsules were dispensed, representing $4541 in savings and a reduction in carbon emissions equivalent to 6,770.5 km driven by a typical gasoline car-enough to drive across Canada from the Pacific to the Atlantic coast. No indications of delayed access or increased workload were reported.

Conclusions: Routine reassessments of wardstock supply of maintenance inhalers or medications that are not acutely needed may be useful in alignment with formulary budget and planetary health.

背景:维持性吸入器通常用于呼吸系统疾病的长期治疗。这些多剂量装置包含数周的药物,价格昂贵,并对全球排放产生重大影响。由于这些药物对治疗急性症状无效,因此有人质疑将这些吸入器放在医院病房是否会造成吸入器的浪费。目的:确定从病房移除维持性吸入器是否会减少吸入器的配发数量。方法:这是一项前瞻性质量改进研究,检查了弗雷泽卫生局的药物使用数据。运行清单报告以确定维护吸入器的位置,以选择要针对的医院站点。在选定的地点将维持性吸入器从病房取出,并将取出前6个月的使用数据与取出后6个月的使用数据进行比较。报告的结果是分配的吸入器数量的变化,每个有效订单日分配的吸入器数量的变化,支出的变化和碳排放的变化。在6个月的后续期间对工作量和访问进行了非正式评估。主要发现:在两家医院的病房中取消维修吸入器后的6个月内,减少了119个吸入器和43个干粉吸入器胶囊的分发,相当于节省了4541美元,减少的碳排放量相当于一辆普通汽油汽车行驶的6,770.5公里——足够从太平洋开到大西洋海岸横穿加拿大。没有迹象显示访问延迟或工作量增加。结论:对非迫切需要的维持性吸入器或药物的病房供应进行常规重新评估可能有助于与规定预算和地球健康保持一致。
{"title":"Breathing easier: removing maintenance inhalers from hospital wardstock for cost savings and waste reduction.","authors":"Elissa S Y Aeng, Peggy Hung, Alfie Chung, Deborah Heidary, Aaron M Tejani","doi":"10.1093/ijpp/riaf047","DOIUrl":"10.1093/ijpp/riaf047","url":null,"abstract":"<p><strong>Background: </strong>Maintenance inhalers are commonly used for long-term management of respiratory conditions. These multidose devices contain several weeks of medication, are expensive, and have significant global emissions impact. As these medications are not useful for managing acute symptoms, it was questioned whether keeping these inhalers in hospital wardstock locations may contribute to inhaler wastage.</p><p><strong>Objective: </strong>To determine if removal of maintenance inhalers from wardstock would reduce the number of inhalers dispensed.</p><p><strong>Methods: </strong>This was a prospective quality improvement study examining medication utilization data within the Fraser Health Authority. An inventory report was run to determine where maintenance inhalers were located to select hospital sites to target. Maintenance inhalers were removed from wardstock at chosen sites and utilization data from 6 months prior to removal were compared to 6 months post-removal. Outcomes reported were change in number of inhalers dispensed, change in number of inhalers dispensed per active-order-day, change in expenditure, and change in carbon emissions. Informal assessments on workload and access were made during the 6-month follow-up period.</p><p><strong>Key findings: </strong>Within 6 months after maintenance inhalers were removed from wardstock at two hospitals, 119 fewer inhalers and 43 fewer dry powder inhaler capsules were dispensed, representing $4541 in savings and a reduction in carbon emissions equivalent to 6,770.5 km driven by a typical gasoline car-enough to drive across Canada from the Pacific to the Atlantic coast. No indications of delayed access or increased workload were reported.</p><p><strong>Conclusions: </strong>Routine reassessments of wardstock supply of maintenance inhalers or medications that are not acutely needed may be useful in alignment with formulary budget and planetary health.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"521-525"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144835029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Guideline adherence for controlling incidence of medication errors: a systematic mixed-method review. 控制用药差错发生率的指南依从性:一项系统的混合方法综述。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf049
Fatemeh Bakhshi, Rebecca Mitchell, Afifeh Khosravi, Mahnaz Antikchi

Background: The article reviews the factors that affect healthcare professionals' adherence to safe medication therapy guidelines, which are important for patient safety and quality of care. The purpose of this review was to further our knowledge on the factors and interventions that contribute to medication guideline adherence among healthcare professionals.

Methods: This review employed a systematic, mixed-methods approach. The authors searched five databases for mixed studies (qualitative, quantitative, and mixed methods) from 2011 to 2023 and appraised them using the Mixed Methods Assessment Tool (MMAT). They extracted and synthesized the data using narrative synthesis.

Results: We identified 20 studies that met the inclusion criteria. We found that the factors influencing medication guideline adherence vary by the roles and settings of healthcare professionals. We classified these factors into four categories: guideline level, personnel level, system level, and leadership level. Guideline-level factors refer to the clarity and consistency of the medication guidelines, policies, or protocols. Personnel-level factors involve the behavior, education, and practice of healthcare professionals. System-level factors relate to the institutional and systemic aspects that support and maintain medication guideline adherence. Leadership-level factors concern the planning and management of medication guideline implementation by healthcare managers. We also discussed the interventions that can improve guideline adherence, including (i) educational programs, (ii) pharmacist-based interventions, and (iii) computerized prescribing programs.

Conclusion: This review provides a typology of factors to help organizations enhance medication safety adherence. The findings highlight the important role of hospital pharmacists in building multifaceted and multidisciplinary programs to address guideline adherence issues.

背景:本文综述了影响医疗保健专业人员遵守安全药物治疗指南的因素,这对患者安全和护理质量很重要。本综述的目的是进一步了解影响医疗保健专业人员依从药物指南的因素和干预措施。方法:本综述采用系统的混合方法。作者检索了2011年至2023年的5个混合研究数据库(定性、定量和混合方法),并使用混合方法评估工具(MMAT)对其进行评价。他们用叙事合成法提取和合成数据。结果:我们确定了20项符合纳入标准的研究。我们发现影响药物指南依从性的因素因医疗保健专业人员的角色和环境而异。我们将这些因素分为四类:指导水平、人员水平、系统水平和领导水平。指南水平因素是指用药指南、政策或方案的清晰度和一致性。人员层面的因素包括医疗保健专业人员的行为、教育和实践。系统级因素涉及支持和维持药物指南依从性的制度和系统方面。领导水平因素涉及医疗保健管理人员对用药指南实施的计划和管理。我们还讨论了可以提高指南依从性的干预措施,包括(i)教育计划,(ii)基于药剂师的干预措施,以及(iii)计算机化处方计划。结论:本综述提供了一个类型的因素,以帮助组织提高药物安全依从性。研究结果强调了医院药剂师在建立多方面和多学科的方案,以解决指南依从性问题的重要作用。
{"title":"Guideline adherence for controlling incidence of medication errors: a systematic mixed-method review.","authors":"Fatemeh Bakhshi, Rebecca Mitchell, Afifeh Khosravi, Mahnaz Antikchi","doi":"10.1093/ijpp/riaf049","DOIUrl":"10.1093/ijpp/riaf049","url":null,"abstract":"<p><strong>Background: </strong>The article reviews the factors that affect healthcare professionals' adherence to safe medication therapy guidelines, which are important for patient safety and quality of care. The purpose of this review was to further our knowledge on the factors and interventions that contribute to medication guideline adherence among healthcare professionals.</p><p><strong>Methods: </strong>This review employed a systematic, mixed-methods approach. The authors searched five databases for mixed studies (qualitative, quantitative, and mixed methods) from 2011 to 2023 and appraised them using the Mixed Methods Assessment Tool (MMAT). They extracted and synthesized the data using narrative synthesis.</p><p><strong>Results: </strong>We identified 20 studies that met the inclusion criteria. We found that the factors influencing medication guideline adherence vary by the roles and settings of healthcare professionals. We classified these factors into four categories: guideline level, personnel level, system level, and leadership level. Guideline-level factors refer to the clarity and consistency of the medication guidelines, policies, or protocols. Personnel-level factors involve the behavior, education, and practice of healthcare professionals. System-level factors relate to the institutional and systemic aspects that support and maintain medication guideline adherence. Leadership-level factors concern the planning and management of medication guideline implementation by healthcare managers. We also discussed the interventions that can improve guideline adherence, including (i) educational programs, (ii) pharmacist-based interventions, and (iii) computerized prescribing programs.</p><p><strong>Conclusion: </strong>This review provides a typology of factors to help organizations enhance medication safety adherence. The findings highlight the important role of hospital pharmacists in building multifaceted and multidisciplinary programs to address guideline adherence issues.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"477-493"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144618076","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring community pharmacy services in Gulf Cooperation Council countries: a scoping review. 探索海湾合作委员会国家的社区药房服务:范围审查。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf041
Solafa M W Noorsaeed, Hisham Alshammari, Natalie Weir, Amanj Kurdi

Introduction: The role of community pharmacists (CPs) is evolving worldwide. However, evidence on the expanding role of CPs in the Gulf Cooperation Council (GCC) countries remains limited.

Objective: This study aimed to describe the type, nature, extent, and/or effectiveness of community pharmacy-based services in GCC countries.

Eligibility criteria: All primary studies involving existing, piloted community pharmacy services or services being explored for future implementation in the GCC countries were eligible for inclusion.

Methods: Ovid MEDLINE, EMBASE, CINAHL, and Scopus were searched from inception to 6 December 2024. Screening and data extraction were performed by two independent reviewers. Results were narratively synthesized.

Results: Overall, 116 studies were included. The majority were from KSA (N = 61, 52.6%) and UAE (N = 38, 32.8%), with none in Oman and Bahrain. Besides the nationally practised dispensing and counselling, tele-pharmacy/E-prescription was implemented nationwide in the UAE and KSA. In some countries, minor ailments management, pregnant and lactating women care, reporting adverse drug reactions, immunization, chronic conditions monitoring, independent prescribing, and health promotion were locally practised by some CPs and under-evaluated. Diabetic education, health screening, and medication therapy management were piloted in some countries and showed promising effectiveness. Humanistic effectiveness was the most assessed outcome (N = 16, 13.8%). The most reported barriers were lack of privacy, time, and training.

Conclusions: The review highlighted the expanding role of CPs in the GCC countries while identifying gaps in practice. Policymakers can utilize the findings to develop strategies for improving practice, ensuring national implementation, and maintaining the quality of services.

社区药剂师(CPs)的作用正在世界范围内发展。然而,关于CPs在海湾合作委员会(GCC)国家扩大作用的证据仍然有限。目的:本研究旨在描述海湾合作委员会国家社区药房服务的类型、性质、程度和/或有效性。资格标准:所有涉及现有试点社区药房服务或正在探索将来在海湾合作委员会国家实施的服务的初步研究都有资格纳入。方法:检索Ovid MEDLINE、EMBASE、CINAHL和Scopus数据库,检索时间为建站至2024年12月6日。筛选和数据提取由两名独立的审稿人进行。对结果进行叙述性综合。结果:共纳入116项研究。大多数患者来自沙特阿拉伯(N = 61, 52.6%)和阿联酋(N = 38, 32.8%),阿曼和巴林无患者。除了全国实行的配药和咨询外,远程药房/电子处方在阿联酋和沙特阿拉伯全国范围内实施。在一些国家,小病管理、孕妇和哺乳期妇女护理、报告药物不良反应、免疫接种、慢性病监测、独立开处方和促进健康是一些初级保健医师在当地实行的,但评价不足。糖尿病教育、健康检查和药物治疗管理在一些国家进行了试点,并显示出良好的效果。人文有效性是评估最多的结果(N = 16, 13.8%)。报告中最多的障碍是缺乏隐私、时间和培训。结论:该审查强调了CPs在海湾合作委员会国家中不断扩大的作用,同时指出了实践中的差距。决策者可以利用调查结果制定改进实践、确保国家实施和保持服务质量的战略。
{"title":"Exploring community pharmacy services in Gulf Cooperation Council countries: a scoping review.","authors":"Solafa M W Noorsaeed, Hisham Alshammari, Natalie Weir, Amanj Kurdi","doi":"10.1093/ijpp/riaf041","DOIUrl":"10.1093/ijpp/riaf041","url":null,"abstract":"<p><strong>Introduction: </strong>The role of community pharmacists (CPs) is evolving worldwide. However, evidence on the expanding role of CPs in the Gulf Cooperation Council (GCC) countries remains limited.</p><p><strong>Objective: </strong>This study aimed to describe the type, nature, extent, and/or effectiveness of community pharmacy-based services in GCC countries.</p><p><strong>Eligibility criteria: </strong>All primary studies involving existing, piloted community pharmacy services or services being explored for future implementation in the GCC countries were eligible for inclusion.</p><p><strong>Methods: </strong>Ovid MEDLINE, EMBASE, CINAHL, and Scopus were searched from inception to 6 December 2024. Screening and data extraction were performed by two independent reviewers. Results were narratively synthesized.</p><p><strong>Results: </strong>Overall, 116 studies were included. The majority were from KSA (N = 61, 52.6%) and UAE (N = 38, 32.8%), with none in Oman and Bahrain. Besides the nationally practised dispensing and counselling, tele-pharmacy/E-prescription was implemented nationwide in the UAE and KSA. In some countries, minor ailments management, pregnant and lactating women care, reporting adverse drug reactions, immunization, chronic conditions monitoring, independent prescribing, and health promotion were locally practised by some CPs and under-evaluated. Diabetic education, health screening, and medication therapy management were piloted in some countries and showed promising effectiveness. Humanistic effectiveness was the most assessed outcome (N = 16, 13.8%). The most reported barriers were lack of privacy, time, and training.</p><p><strong>Conclusions: </strong>The review highlighted the expanding role of CPs in the GCC countries while identifying gaps in practice. Policymakers can utilize the findings to develop strategies for improving practice, ensuring national implementation, and maintaining the quality of services.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"458-476"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144247831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A systematic analysis of medicine information pertaining to race and ethnicity terms for 100 top selling medicines in the USA. 对美国100种最畅销药物的种族和民族术语的医学信息进行系统分析。
IF 1.8 Q3 PHARMACOLOGY & PHARMACY Pub Date : 2025-10-03 DOI: 10.1093/ijpp/riaf048
Nancy A Alvarez, Wendy DeBano, Jason Agundez, Rion Poland, Brian L Erstad

Objectives: The primary objective of the study focused on the analysis of the terminology used to describe race and/or ethnicity in package inserts for the 100 top-selling medicines in 2021 and to the evaluation of this data based on overall terminology use frequency, terminology use frequency by medication class, and frequency of terminology appearance under specific insert headings.

Methods: Data collection involved reviewing package inserts for 100 top-selling medicines approved in the USA starting with the top 10 medicines followed by the remaining 90 medicines on the list. For the initial 10 medicines, a sample package insert was obtained from the DailyMed website, a resource supported by the US National Library of Medicine and analyzed for the explicit use of race or ethnicity terminology. Identified terms were coded and a list of relevant terms was compiled. A sample package insert for each of the other 90 medicines was analyzed using the list of relevant terminology. A final list to represent the use and quantification of race and ethnicity terminology was compiled.

Key findings: This qualitative study revealed that some of the terminology in US medicine information labeling is not consistent with the current wording recommended in FDA guidance for race and ethnicity data collection during clinical trials and other studies. Another finding of this analysis is variation in the frequency of use of race and ethnicity terminology relative to the medicine category and sections of the package insert.

Conclusions: Healthcare providers must be cautious when evaluating package inserts, especially race/ethnicity-related terminology that may not reflect current medicine development requirements or when changes occur to tools previously influenced by information used in clinical trials.

研究的主要目的是分析2021年100种最畅销药物说明书中用于描述种族和/或民族的术语,并根据总体术语使用频率、药物类别术语使用频率和特定说明书标题下术语出现频率对这些数据进行评估。方法:数据收集涉及审查在美国批准的100种最畅销药物的说明书,从前10种药物开始,然后是清单上其余90种药物。对于最初的10种药物,从美国国家医学图书馆支持的资源DailyMed网站上获得了样品包装说明书,并分析了种族或民族术语的明确使用。对已识别的术语进行编码,并编制了一份相关术语清单。使用相关术语清单分析了其他90种药物的样品包装说明书。编制了一份代表种族和族裔术语的使用和量化的最后清单。主要发现:本定性研究显示,美国药品信息标签中的一些术语与FDA在临床试验和其他研究期间种族和民族数据收集指南中推荐的当前措辞不一致。该分析的另一个发现是,相对于药品类别和说明书各部分,种族和族裔术语的使用频率存在差异。结论:医疗保健提供者在评估药品说明书时必须谨慎,特别是与种族/民族相关的术语,这些术语可能不能反映当前的药物开发要求,或者当先前受临床试验中使用的信息影响的工具发生变化时。
{"title":"A systematic analysis of medicine information pertaining to race and ethnicity terms for 100 top selling medicines in the USA.","authors":"Nancy A Alvarez, Wendy DeBano, Jason Agundez, Rion Poland, Brian L Erstad","doi":"10.1093/ijpp/riaf048","DOIUrl":"10.1093/ijpp/riaf048","url":null,"abstract":"<p><strong>Objectives: </strong>The primary objective of the study focused on the analysis of the terminology used to describe race and/or ethnicity in package inserts for the 100 top-selling medicines in 2021 and to the evaluation of this data based on overall terminology use frequency, terminology use frequency by medication class, and frequency of terminology appearance under specific insert headings.</p><p><strong>Methods: </strong>Data collection involved reviewing package inserts for 100 top-selling medicines approved in the USA starting with the top 10 medicines followed by the remaining 90 medicines on the list. For the initial 10 medicines, a sample package insert was obtained from the DailyMed website, a resource supported by the US National Library of Medicine and analyzed for the explicit use of race or ethnicity terminology. Identified terms were coded and a list of relevant terms was compiled. A sample package insert for each of the other 90 medicines was analyzed using the list of relevant terminology. A final list to represent the use and quantification of race and ethnicity terminology was compiled.</p><p><strong>Key findings: </strong>This qualitative study revealed that some of the terminology in US medicine information labeling is not consistent with the current wording recommended in FDA guidance for race and ethnicity data collection during clinical trials and other studies. Another finding of this analysis is variation in the frequency of use of race and ethnicity terminology relative to the medicine category and sections of the package insert.</p><p><strong>Conclusions: </strong>Healthcare providers must be cautious when evaluating package inserts, especially race/ethnicity-related terminology that may not reflect current medicine development requirements or when changes occur to tools previously influenced by information used in clinical trials.</p>","PeriodicalId":14284,"journal":{"name":"International Journal of Pharmacy Practice","volume":" ","pages":"508-514"},"PeriodicalIF":1.8,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144484334","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Pharmacy Practice
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1